Lozovaya, N.
Nardou, R.
Tyzio, R.
Chiesa, M. http://orcid.org/0000-0003-1500-4285
Pons-Bennaceur, A.
Eftekhari, S.
Bui, T.-T.
Billon-Grand, M.
Rasero, J. http://orcid.org/0000-0003-1661-2856
Bonifazi, P.
Guimond, D.
Gaiarsa, J.-L. http://orcid.org/0000-0001-7354-0559
Ferrari, D. C. http://orcid.org/0000-0001-7418-7873
Ben-Ari, Y. http://orcid.org/0000-0001-6208-8480
Article History
Received: 14 February 2019
Accepted: 11 June 2019
First Online: 25 June 2019
Competing Interests
: N.L., R.N., R.T., M.C., S.E., T.-T.B., D.G., D.C.F. and Y.B.-A. are or were paid by Neurochlore, a biotech company dedicated to the development of treatments for children with autism. N.L., R.N., R.T., D.C.F. and Y.B.-A. are shareholders of Neurochlore. Y.B.-A. is CEO of Neurochlore.